Journal article
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
GA McArthur, I Puzanov, R Amaravadi, A Ribas, P Chapman, KB Kim, JA Sosman, RJ Lee, K Nolop, KT Flaherty, J Callahan, RJ Hicks
Journal of Clinical Oncology | Published : 2012
Abstract
Purpose: Imaging with [18F]fluorodeoxyglucose (FDG) -positron emission tomography (PET) allows early recognition of a response to agents that target key driver mutations in human cancer. We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma. Patients and Methods: Baseline and day 15 FDG-PET was evaluated in 31 patients with advanced melanoma treated in a phase I study of dose escalation of vemurafenib (PLX06-02), which included four patients treated at subtherapeutic doses and 24 patients treated at 960 mg twice a day, which is the maximum-tolerated dose of vemurafenib. Results: All 27 patients treated at potentially therapeutic level..
View full abstractGrants
Awarded by Victorian Cancer Agency
Awarded by National Health and Medical Research Council
Funding Acknowledgements
[ "Supported by Plexxikon and Hoffman-La Roche and in part by Grants No. EOI09_27 from the Victorian Cancer Agency and APP1002655 from the National Health and Medical Research Council and by the Cancer Council of Victoria and the Sir Edward Weary Dunlop Clinical Research Fellowship from the Cancer Council of Victoria.", "Research Funding: Grant A. McArthur, Pfizer; Paul Chapman, Hoffman-La Roche/Genentech; Kevin B. Kim, Roche; Jeffrey A. Sosman, Bristol-Myers Squibb, GlaxoSmithKline" ]